- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01203527
A Study of the Pharmacology of Tamiflu in Pregnancy
A Study of the Pharmacology of Oseltamivir (Tamiflu-Roche) in Pregnancy
Přehled studie
Postavení
Detailní popis
The emergence of the novel H1N1 influenza virus has raised concern among public health officials and the public alike. Although initial reports suggested that the risk of serious disease or death was less than initially feared, continued experience suggests that the disease will have a major impact on the public's health. To address this urgent public health challenge, the centers of the Obstetric-Fetal Pharmacology Research Units Network (OPRU) will recruit a total of 75 pregnant women (25 per trimester with singletons pregnancies) who are receiving oseltamivir for supposed influenza infection. When possible, we will recruit women with twin gestation to determine if fetal number affects the drugs pharmacokinetics. We do not anticipated a significant number of multi-fetal gestations (< 10) but even limited data might prove useful in this population given the tremendous change in renal drug clearance that is normally seen in this group of women. An additional 25 healthy non-pregnant women will be studied to define pregnancy- related changes in the PK of oseltamivir and the carboxylate.
We will study each woman once during therapy, performing steady state pharmacokinetic analyses. This study will be performed after 3 days of oral therapy to optimize the possibility that steady state concentrations have been achieved.
We will:
- collect biological fluids (plasma and urine) to further characterize the pharmacology of the drug;
- collect a check swab for DNA to allow study of the impact of single nucleotide polymorphisms on drug handing and disease expression;
- develop an assay or partner with others to develop an assay for oseltamivir and the primary metabolite, oseltamivir carboxylate;
- compare the pharmacokinetics of oseltamivir and its metabolite in each trimester of pregnancy to evaluate whether gestational age has an impact on the drug's pharmacokinetics;
- assess the impact of fetal number on the drug's pharmacokinetics;
- ask all participants about GI tolerance to the drug and any side effects they may be experiencing, especially related to mood and psychiatric well being; and
- on all pregnant subjects studied, when possible, we will obtain at delivery maternal and umbilical cord blood to evaluate placental transport especially in those who deliver proximate (within 3 days) to drug treatment.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University School of Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- University of Pittsburgh
-
-
Texas
-
Galveston, Texas, Spojené státy, 77555
- University of Texas Medical Branch
-
-
Washington
-
Seattle, Washington, Spojené státy, 98195
- University of Washington
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Taking or about to start oral oseltamivir for presumed influenza viral infection or for prophylaxis
- Able to give informed consent
- Pregnant female with singleton or multifetal gestation or healthy non-pregnant female (ancillary study)
Exclusion Criteria:
- Unable to take medication orally
- Renal failure - creatinine > 1.5
- Hct <28
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
Kohorty a intervence
Skupina / kohorta |
---|
Tamiflu use during first trimester
This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
|
Tamiflu use during second trimester
This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
|
Tamiflu use during third trimester
This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
|
Tamiflu use in non-pregnant women
This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Apparent oral clearance of oseltamivir in singletons
Časové okno: At the time of treatment
|
At the time of treatment
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Apparent oral clearance of oseltamivir in twins
Časové okno: At the time of treatment
|
At the time of treatment
|
Apparent renal clearance of oseltamivir carboxylate in non-pregnant women (ancillary study)
Časové okno: At the time of treatment
|
At the time of treatment
|
Concentration of oseltamivir carboxylate and oseltamivir at times 0 and 12h to ascertain steady state status
Časové okno: At the time of treatment
|
At the time of treatment
|
Plasma esterase activity. (ancillary study)
Časové okno: At the time of treatment
|
At the time of treatment
|
Maternal side effects -GI upset, pregnancy loss, neuropsychiatric disorder
Časové okno: At the time of treatment
|
At the time of treatment
|
Maternal and cord blood oseltamivir and oseltamivir carboxylate concentrations
Časové okno: At delivery
|
At delivery
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Richard Beigi, MD, University of Pittsburgh
- Vrchní vyšetřovatel: Steve Caritis, MD, University of Pittsburgh
- Vrchní vyšetřovatel: Raman Venkataramanan, PhD, University of Pittsburgh
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- OPRU Tamiflu
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .